EUCTR2007-005579-33-BG进行中（未招募）不适用
Efficacy and tolerability of EPs® 7630 solution in patients (>=18 years old) with Acute Rhinopharyngitis (ARP)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1) Male and female patients >= 18 years old
- •(2) Written informed consent
- •(3) Patients suffering from acute rhinopharyngitis (ARP)
- •(4) Presence of
- •(a) both major rhinopharyngitis-relevant symptoms (RPS) (nasal discharge and sore throat) with >= 2 points each and at least two minor RPS (nasal congestion, sneezing, scratchy throat, hoarseness, cough, headache, muscle aches, or fever) with >= 2 points each, or
- •(b) one major RPS with >= 2 points and at least three minor RPS with >= 2 points each
- •(5) Start of the acute rhinopharyngitis-relevant symptoms (RPS) 24-72 hours prior to inclusion into the study
- •(6) Patients with willingness and ability to comply with all procedures of the trial and attend all scheduled visits at the investigational site.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(1) Obstructive anatomic lesions in the nasopharynx such as nasal polyps, or severe septal deviations
- •(2) Previous surgery (within the last 12 months prior to inclusion into the study) or need for surgery of the nose or paranasal sinuses incl. sinus puncture
- •(3) Presence of any acute ENT diseases other than rhinopharyngitis and/or presence of respiratory tract disease (e.g. tonsillitis, sinusitis, otitis, bronchitis, pneumonia)
- •(4) Patients with allergic rhinitis
- •(5) Chronic lung diseases (e.g. chronic bronchitis, COPD, bronchial asthma, cystic fibrosis, active pulmonary tuberculosis, lung cancer)
- •(6) Recurrent tonsillitis or otitis of > 3 episodes during the last 12 months prior to enrolment into the study
- •(7) Recurrent bronchitis of > 6 episodes during the past 12 months prior to enrolment into the study
- •(8) Recurrent sinusitis of > 3 episodes during the past 12 months prior to enrolment into the trial or chronic sinusitis (symptoms lasting for > 1 month)
- •(9) Previous treatment with antibiotics, glucocorticosteroids or antihistamines within the last
- •4 weeks prior to enrolment into the trial
- •(10) Previous (within the last 6 weeks prior to inclusion into the clinical trial) or concomitant treatment with anti-coagulants
- •(11) Previous treatment with cold medications (e.g. decongestants, local anesthetics, zinc, Echinacea, vitamin C >= 100 mg per day), anti-inflammatories, anti-tussiva, mucolytics, secretolytics, Pelargonium sidoides preparations, herbal treatment for cold, or pain relief medications (e.g. aspirin, paracetamol) within the last 7 days prior to enrolment into the trial
- •(12) Concomitant medications that might impair the interpretation of trial results (e.g. antibiotics, glucocorticosteroids, antihistamines, any cold medications such as decongestants, zinc, Echinacea, vitamin C >= 100 mg per day , anti-inflammatories, secretolytics, anti-tussiva, mucolytics, herbal medications other than the study medication, or pain relief medications other than paracetamol)
- •(13) Known or suspected hypersensitivity to the investigational drug
- •(14) Severe cardiovascular disease, unstable diabetes mellitus, or immunosuppression
- •(15) Known severe renal or hepatic dysfunction (serum creatinine, serum AST, ALT or alkaline phosphatase >3 times above the upper limit of normal values) at any time during the past 12 months prior to enrolment into the trial
- •(16) Significant symptoms within the last 6 months prior to enrolment into the study, e.g. un-unintentional weight loss, or any other sign indicating serious or malignant disease
- •(17) Evidence of any malignant disease during the past 5 years prior to enrolment into the trial
- •(18) Heavy smoking (= 25 cigarettes per day)
- •(19) Intake of >= 500 mg caffeine per day
- •(20) Known alcohol or drug abuse
- •(21) Patients with tendency to bleed, specially nose or gingival bleeding
- •(22) Known gastrointestinal disorders (e.g. partial or total gastrectomy, enterectomy, inflammatory bowel disease, celiac disease, symptomatic lactose intolerance, other disorders associated with chronic diarrhea)
- •(23) Females of child-bearing potential with no adequate contraception
- •(24) Pregnancy or lactation
- •(25) Patients participating in another clinical trial at the same time or have taken part in a clinical trial during the last 4 weeks before inclusion into this study
- •(26) Irresponsible patients or those unable to understand nature, meaning and consequences of the trial
研究者
相似试验
进行中（未招募）
不适用
Efficacy and tolerability of EPs 7630 solution in patients (> = 18 years old) with Acute Rhinopharyngitis (ARP)Adult patients are suffering at an acute Rhinopharyngitis. They will take 10 days 3x 30 drops per day of the investigational product and they will have 4 Visits.EUCTR2007-004923-39-DEDr. Willmar Schwabe GmbH & Co. KG
已完成
不适用
Safety and intake effect of EPs® 7630 (an extract of the roots of Pelargonium sidoides)Common coldISRCTN35425744Dr. Willmar Schwabe GmbH & Co. KG (Germany)798
已完成
不适用
Efficacy of EPs 7630 compared to placebo in the treatment of acute bronchitisBronchitisAcute bronchitisRespiratoryISRCTN60790910ISO Arzneimittel GmbH & Co KG (Germany)205
进行中（未招募）
1 期
Safety and intake effect of EPs®7630 (an extract from the roots of Pelargonium sidoides)common coldMedDRA version: 16.1 Level: LLT Classification code 10010106 Term: Common cold System Organ Class: 100000004862EUCTR2013-004977-28-GBDr. Willmar Schwabe GmbH & Co. KG798
尚未招募
Unknown
Evaluation of an Investigational Product in the Restructuring of the skin protection barrierDiaper RashM01.774.500RBR-10brpqhzMedcin Instituto da Pele Ltda